ArQule Signs c-Met Inhibitor, Discovery Platform Deals With Daiichi-Sankyo
This article was originally published in The Pink Sheet Daily
Executive Summary
Two deals bring the biotech $75 million upfront, plus research and clinical development funding.
You may also be interested in...
Deals Of The Week: Will Heated Competition To Buy Out Ache Laboratorios Muddy The Brazilian Waters?
Pfizer, Novartis and Abbott reportedly are battling to buy out family-owned Ache, Brazil’s leader in prescription drug sales. Plus deals involving AstraZeneca and AlphaCore, Pfizer and Bind Therapeutics and Merck and Ra Pharma.
ArQule Gets Early-Stage Cancer Program Back From Daiichi
The Japanese pharma has elected to return rights to an early-stage cancer development program to ArQule, but the biotech reassured investors the two companies will continue to move forward on their beleaguered late-stage oncology endeavor.
ArQule Pleads Tivantinib’s Promise In Liver Cancer After Lung Cancer Blow-up
Progression-free survival benefit fails to translate into overall survival in Phase III NSCLC study of c-Met inhibitor tivantinib, partnered with Daiichi Sankyo. ArQule shifts focus to an imminent, targeted second-line Phase III study of high-Met expressing hepatocellular cancer.